Close Menu

Serimmune: Noah Nasser, Bill Welch

Aug 06, 2019

Goleta, California-based Serimmune has appointed Noah Nasser as CEO and Bill Welch to its board of directors.

Prior to Seriummne, Nasser served as chief commercial officer at Human Longevity. Before working at Human Longevity, Nasser served as chief commercial officer at Counsyl. In addition, he held leadership positions at AltheaDx and Verinata Health. 

Welch is currently a venture partner at Illumina Ventures. Before joining Illumina Ventures, Welch served as CEO at Trovagene. Prior to Trovagene, Welch was president and CEO at Sequenom. Before working at Sequenom, Welch served as CCO at Monogram Biosciences. Prior to Monogram, Welch held progressive management positions at Abbot Laboratories. 

More Like This

Dec 02, 2019

NeoGenomics: Lawrence Weiss

NeoGenomics has appointed Lawrence Weiss the company's chief medical officer, effective Nov. 25. He has been NeoGenomics' CSO since December 2018. Prior to that, he had been the firm's director of pathology services since March 2016. Before joining Neogenomics, Weiss was at Clarient Diagnostic Services as a pathologist then as laboratory director. 

 

 

Dec 02, 2019

Bionano Genomics: Mike Ward

Bionano Genomics CFO Mike Ward has notified the firm of his resignation, effective Dec. 6. "Ward's resignation is not the result of any disagreement with the company," Bionano Genomics said last week in a document filed with the US Securities and Exchange Commission.

Nov 22, 2019

Inteliquet: Marie Lamont

Inteliquet has named Marie Lamont interim president and chief operating officer. She replaces former CEO, President, and COO Carla Balch, who left Inteliquet to "pursue other opportunities," the company said. Lamont had been president of patient services at Dolman Life Science Services. Previously, she held several senior positions at Genzyme. Inteliquet rebranded from TransMed Systems earlier this year.

Nov 21, 2019

NYGC: Mary-Claire King

Mary-Claire King has joined the New York Genome Center faculty on a consulting basis as a senior associate core member. She is the American Cancer Society Professor in the Department of Genome Sciences and Medicine at the University of Washington in Seattle. At the NYGC, she will work closely with Thomas Lehner, the center's recently appointed scientific director of neuropsychiatric disease, and act as a senior adviser to both Lehner and Tom Maniatis, the center's CEO.  

Nov 21, 2019

Elucidata: Richard Kibbey, Nick Pullen, Avi Ma'ayan

Elucidata has formed a scientific advisory board comprising Richard Kibbey, Nick Pullen, and Avi Ma'ayan. Kibbey is associate professor of medicine (endocrinology) and cellular & molecular biology at the Yale School of Medicine. Pullen is the scientific cofounder of Elucidata, and has more than 20 years of experience in the pharmaceutical industry with Pfizer, Roche, and most recently Celgene. Ma'ayan is director of the Mount Sinai Center for Bioinformatics and a professor of bioinformatics in Mount Sinai's Department of Pharmacological Sciences.

Nov 20, 2019

Twist Bioscience: Patrick Finn

Patrick Finn has been promoted from senior VP of commercial operations to chief operating officer of Twist Bioscience, a new position at the company. Prior to joining Twist in 2015, Finn was VP of sales at Enzymatics, and before that, he held various positions at Agilent Technologies, Beckman Coulter, Invitrogen, and GE Healthcare/Amersham International. He holds a PhD in nucleic acid chemistry from the University of Southampton in England and a BSc in chemistry from Heriot-Watt University in Scotland.

Nov 20, 2019

GenapSys: Frank Witney, Rakesh Sachdev, Hamid Moghadam

In connection with its recent funding round, GenapSys has made several appointments to its board of directors. Joining the board are Frank Witney, former CEO of Affymetrix and Dionex; Rakesh Sachdev, former CEO of Sigma Aldrich and Platform Specialty Products; and Hamid Moghadam, CEO and chairman of Prologis.

Nov 20, 2019

BioTeam: Ari Berman, Stan Gloss

Ari Berman has been promoted from VP of consulting to CEO of BioTeam. He replaces company cofounder Stan Gloss, who will become BioTeam's chief marketing officer. Berman holds a PhD in molecular biology from the University of Texas at Austin.

Nov 20, 2019

ATCC: Raymond Stapleton

Raymond Stapleton has been appointed as president and chief operating officer of biological materials resource and standards organization ATCC. Previously, he was senior VP of technical operations at Iovance Biotherapeutics, and before that, he held various roles at Merck. Stapleton holds a PhD in microbial ecology from the University of Tennessee and a bachelor's degree in biology from Mary Washington College in Fredericksburg, Virginia.

Nov 20, 2019

Sophia Genetics: Milton Silva-Craig

Sophia Genetics has named Milton Silva-Craig to its board of directors. Silva-Craig currently serves as CEO of Q-Centrix, a maker of healthcare data management technology. He previously headed the healthcare business unit of TransUnion and was president and CEO of Emageon, a health imaging software company that he helped lead through an initial public offering before that firm was sold to revenue-cycle management technology vendor Health Systems Solutions.

Nov 14, 2019

SEngine Precision Medicine: Astrid Margossian

SEngine Precision Medicine has hired Astrid Margossian as chief medical officer. Margossian, a surgeon, medical oncologist, and cancer researcher with MD and PhD degrees, previously established and served as medical director of Baylor College of Medicine's Breast Center Buenos Aires and Breast Cancer Research Biobank, which focuses on biomarker discovery for breast cancer. 

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

Nov 13, 2019

Danaher: Jessica Mega, Pardis Sabeti

Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.

Sabeti has been an investigator at Howard Hughes Medical Institute since November 2015, and is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University. She also teaches in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Sabeti holds degrees from the Massachusetts Institute of Technology, University of Oxford, and Harvard Medical School. 

Nov 13, 2019

Human Longevity: Thomas Caskey

Human Longevity has appointed Thomas Caskey as chief medical officer. Caskey is a professor of molecular and human genetics at the Baylor College of Medicine, and is board-certified in internal medicine, medical genetics, and molecular genetics. He is a member of the National Academy of Sciences, Institute of Medicine, Royal Society of Canada and the Texas Academy of Medicine, Engineering and Science. He is also past president of the American Society of Human Genetics and the Human Genome Organization. 

Nov 13, 2019

Abbott: Robert Ford, Miles White

Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board. 

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.